Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01656278
Other study ID # IMAGINE-RA
Secondary ID
Status Completed
Phase N/A
First received July 5, 2012
Last updated June 22, 2017
Start date March 2012
Est. completion date May 2017

Study information

Verified date June 2017
Source King Christian X´Hospital for Rheumatic Diseases
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to examine whether an magnetic resonance imaging (MRI) -guided treatment strategy based on a predefined treatment algorithm can prevent progression of erosive joint damage, increase remission rate and improve functional level in the short and long term in patients with rheumatoid arthritis (RA).


Description:

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease. Patients typically experience pain, functional impairment and reduced quality of life, and are at risk of developing progressive joint damage. The disease primarily affects the small joints of the hands and feet. The current treatment strategy involves early and intensive treatment with close clinical follow up, which attempts to control the disease and avoid inflammation and thereby prevent pain, improve functional level and avoid joint damage. It is therefore important for optimal treatment of RA patients that methods used for diagnosis, disease monitoring and prognostication are highly sensitive. Erosive joint damage occurs early in the disease. Joint deformity is irreversible and causes serious functional impairment. Early and intensive treatment with close monitoring of the inflammation can slow the destructive disease and prevent function loss. However, it has been demonstrated that patients who are shown by conventional clinical and biochemical examination to have low disease activity or to be in remission can still have progressive joint damage. This demonstrates that current clinical/biochemical methods used in daily clinical practice are not sufficiently sensitive and other methods are required for the monitoring of disease activity and prognostication.

The presence of erosions (shown by X-ray examination) as well as anti-cyclic citrullinated peptide (anti-CCP) antibodies and bone marrow oedema (osteitis) on magnetic resonance imaging (MRI), are all independent predictors of subsequent radiographic progression. Bone marrow oedema has been shown to be the strongest independent predictor in early RA and MRI therefore has significant prognostic value.

It is therefore possible that supplementing conventional clinical and biochemical examinations of RA patients with MRI, and intensifying treatment where bone marrow oedema is present, will help reduce disease activity, avoid progressive joint damage and prevent function loss.

The current study is therefore based on the following hypothesis:

By supplementing conventional clinical and biochemical examination of RA patients with low disease activity/in remission with MRI and intensifying treatment in the case of sub-clinical inflammation as measured by the presence of bone marrow oedema, it is possible to prevent radiographic erosive progression, improve functional level and enable more patients to achieve clinical remission.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date May 2017
Est. primary completion date May 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age > 18 years

- RA according to ACR (American College of Rheumatology)/EULAR (European League Against Rheumatism) 2010 criteria.

- Anti-CCP positivity

- Erosions on conventional X-ray of hands, wrists and/or feet

- No clinically swollen joints

- DAS28 (4 variable, CRP) < 3.2

- DMARD monotherapy treatment OR combination treatment, in the form of 2- or 3-drug therapy. If the patient is undergoing 3-drug therapy, at least one of the preparations must be administered at less than the "maximum inclusion dose"*

- Unchanged anti-rheumatic treatment in the previous 6 weeks or more

- No previous treatment with biological medication

- No contra-indications for TNF-alpha-inhibiting treatment

- No contra-indications for MRI

- s-creatinine within normal range

- Ability and willingness to give written and oral informed consent and fulfil the requirements of the study programme with reference to the protocol

- Maximum "inclusion dose" is defined as: MTX 25 mg/week (or maximum tolerated dose if 25 mg/week is not tolerated), SSZ 2g/day (or maximum tolerated dose if 2 g/day is not tolerated) and HCQ 200 mg/day (or maximum tolerated dose if 200 mg/day is not tolerated)

Exclusion Criteria:

- Previous or current biological treatment

- Known intolerance to methotrexate treatment which means that the patient is not able to tolerate a minimum of MTX 7.5 mg (minimum dose).

- DMARD 3-drug therapy at maximum tolerated/maximum "inclusion dose"*

- I.m, intra-articular or i.v glucocorticoid administration = 6 weeks prior to inclusion

- Oral glucocorticoid administration > 5 mg/day

- Changes in oral glucocorticoid dose < 3 months prior to inclusion

- Myocrisin treatment

- Affected liver enzymes > 2 x the upper limit of normal at the time of screening

- Current and/or imminent wish to become pregnant

- Contra-indications for TNF-alpha-inhibiting treatment

- Contra-indications for MRI

- Known alcohol/drug abuse

- Inability to give informed consent

- Inability to cooperate with the study programme due to physical or mental reasons

Study Design


Intervention

Procedure:
Magnetic resonance imaging (MRI)
Treatment algorithm based on conventional biochemical/clinical examinations AND MRI of unilateral 2nd to 5th MCP joints and wrist on dominant side. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of "unsatisfactory inflammatory activity", which is defined as the presence of at least one physically swollen joint and DAS28>3.2 AND/OR MRI-detected bone marrow oedema score > 0 (RAMRIS-score)
Other:
Conventional biochemical and clinical examinations
Treatment algorithm based on conventional biochemical and clinical examinations. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of "unsatisfactory inflammatory activity", which is defined as the presence of at least one clinically swollen joint and DAS28>3.2

Locations

Country Name City State
Denmark Dep. of Rheumatology Aarhus Hospital Aarhus
Denmark Dep. of Rheumatology Frederiksberg Hospital Copenhagen
Denmark Dep. of Rheumatology Gentofte Hospital Copenhagen
Denmark Dep. of Rheumatology Glostrup Hospital Copenhagen
Denmark Dep. of Rheumatology King Christian X´Hospital for Rheumatic Diseases Graasten
Denmark Department of Rheumatology University Hospital Vendsyssel Hjørring
Denmark Dep. of rheumatology Odense Hospital Odense
Denmark Dep. of Rheumatology Silkeborg Hospital Silkeborg
Denmark Dep. of Rheumatology Slagelse Hospital Slagelse

Sponsors (5)

Lead Sponsor Collaborator
Professor of Rheumatology, MD, DMSci, Kim Horslev-Petersen Abbott, Glostrup University Hospital, Copenhagen, King Christian X´Hospital for Rheumatic Diseases, Slagelse Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Dynamic MRI Dynamic MRI variable (including initial rate of enhancement (IRE) and maximum enhancement (ME)). 24 month
Primary DAS28 remission (<2.6) 24 month
Primary No radiographic progression (assessed by the Sharp/vdHeijde method). 24 month
Secondary No radiographic progression (Sharp/vdHeijde score). No radiographic progression (Sharp/vdHeijde score) from 0-12 and 12-24 months and change in Sharp/vdHeijde score from 0-12, 0-24 and 12-24 months. 24 month
Secondary No MRI erosion (RAMRIS) score No progression in MRI erosion (RAMRIS) score from 0-12 and 12-24 months and change in MRI erosion (RAMRIS) score from 0-12, 0-24 and 12-24 months. 24 month
Secondary MRI synovitis (RAMRIS) score MRI synovitis (RAMRIS) score at 12 and 24 months 24 months
Secondary MRI bone marrow oedema (RAMRIS) score MRI bone marrow oedema (RAMRIS) score at 12 and 24 months 24 months
Secondary HAQ score Changes in HAQ score from 0-12 and 0-24 months 24 month
Secondary SF-36 score Changes in SF-36 score from 0-12 and 0-24 months 24 month
Secondary EQ-5D score Changes in EQ-5D score from 0-12 and 0-24 months 24 month
Secondary ACR/EULAR 2011 remission ACR/EULAR 2011 remission at 12 and 24 months 24 month
Secondary DAS28 DAS28 at 12 and 24 month 24 month
Secondary DAS28 remission (<2.6) at 12 months 24 months
Secondary biomarker analyses 24 month
See also
  Status Clinical Trial Phase
Terminated NCT01682512 - Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis Phase 3
Completed NCT00539760 - A Phase I Rheumatoid Arthritis Study in Healthy Volunteers Phase 1
Active, not recruiting NCT03312465 - Anatomical Shoulder Domelock System Study
Completed NCT01208181 - A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107) Phase 3
Completed NCT03254810 - Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects Phase 1
Completed NCT01711814 - A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study Phase 2
Completed NCT03315494 - Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers Phase 1
Withdrawn NCT03241446 - Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA) Phase 1
Completed NCT02553018 - Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe Phase 3
Completed NCT02748785 - MTX Discontinuation and Vaccine Response Phase 4
Active, not recruiting NCT02260778 - Treat-to-target in RA: Collaboration To Improve adOption and adhereNce N/A
Completed NCT02569736 - Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
Completed NCT01750931 - This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets. Phase 2
Not yet recruiting NCT01154647 - Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes N/A
Withdrawn NCT01204138 - Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA Phase 2
Completed NCT00913458 - Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis Phase 4
Completed NCT00973479 - An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy Phase 3
Completed NCT00975130 - Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2) Phase 3
Completed NCT00550446 - A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis Phase 2
Completed NCT00660647 - Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA) Phase 3